Evidence map›Paper›PMID 23988642›Full record

ArticleStroke2013

Deficient eNOS phosphorylation is a mechanism for diabetic vascular dysfunction contributing to increased stroke size.

Qian Li, Dmitriy Atochin, Satoshi Kashiwagi, John Earle, Annie Wang, Emiri Mandeville, Kazuhide Hayakawa, Livius V d'Uscio, Eng H Lo, Zvonimir Katusic and 2 more

Open access · bronzeAbstract read
In one paragraph

Article in Stroke, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed, 1 pooled it
3.2field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

37 citing papers in PubMed, 1 synthesis or guideline pooled it, 63 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Review
  6. Targeting hypoxia and thrombospondin-2 in diabetic wound healing.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2024
    Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Photobiomodulation and nitric oxide signaling.Nitric oxide : biology and chemistry · 2023
    Review
  13. Article
  14. Article
  15. Article
  16. Review
  17. Review
  18. Article
  19. Article
  20. Endothelial NOS: perspective and recent developments.British journal of pharmacology · 2019
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 1 institution in 1 country.

Qian LiFrom the Cardiovascular Research Center (Q.L., D.A., S.K., J.E., A.W., P.L.H.) and Neuroprotection Research Laboratory (E.M., K.H., E.H.L.), Massachusetts General Hospital and Harvard Medical School, Boston, MA; the Departments of Anesthesiology and Molecular, Pharmacology, and Experimental Therapeutics, Mayo Clinic, Rochester, MN (L.V.U., Z.K.); and the Department of Pharmacology and Vascular Biology and Therapeutics Program, Yale University School of Medicine, New Haven, CT (W.S.).
Dmitriy Atochin
Satoshi Kashiwagi
John Earle
Annie Wang
Emiri Mandeville
Kazuhide Hayakawa
Livius V d'Uscio
Eng H Lo
Zvonimir Katusic
William Sessa
Paul L Huang
Mayo Clinic · US

Funding

REGULATION OF CEREBRAL BLOOD FLOWR01NS033335 · NINDS · MASSACHUSETTS GENERAL HOSPITAL · PI HUANG, PAUL L. · 1994 to 2012
$4.2M
NITRIC OXIDE SYNTHASE ISOFORMS IN ATHEROSCLEROSISR01HL057818 · NHLBI · MASSACHUSETTS GENERAL HOSPITAL · PI HUANG, PAUL L. · 1998 to 2006
$1.8M
NHLBI NIH HHS R01 HL057818NHLBI NIH HHS R01 HL57818NINDS NIH HHS NS33335NINDS NIH HHS R01 NS033335
6 · The paper itself

Abstract

background and purposePhosphorylation of eNOS, an important post-translational modulator of its enzymatic activity, is reduced in diabetes mellitus. We hypothesized that modulation of eNOS phosphorylation could overcome diabetic vascular dysfunction and improves the outcome to stroke.

methodsWe used the db/db mouse model of type 2 diabetes mellitus. We mated db/db mice with eNOS knock-in mice that carry single amino acid mutations at the S1176 phosphorylation site; the phosphomimetic SD mutation (serine replaced by aspartate) shows increased eNOS enzymatic activity, whereas the unphosphorylatable SA mutation (serine replaced by alanine) shows decreased eNOS activity. We characterized the vascular anatomy, baseline physiological parameters, and vascular reactivity. We used the middle cerebral artery occlusion model of stroke and measured infarct volume and neurological deficits.

resultsdb/db mice showed diminished eNOS phosphorylation at S1176. eNOS SD and SA mutations do not change the vascular anatomy at the Circle of Willis, brain capillary density, heart rate, or arterial blood gases of db/db mice. The eNOS SD mutation, but not the SA mutation, lowers blood pressure and improves vascular reactivity to acetylcholine in db/db mice. The eNOS SD mutation reduces stroke size and neurological deficit after middle cerebral artery occlusion.

conclusionsDiminished eNOS phosphorylation is a mechanism of vascular dysfunction in db/db mice. We show here that modulation of the eNOS S1176 phosphorylation site in db/db mice is associated with improved vascular reactivity and improved outcome to stroke after middle cerebral artery occlusion.

Indexed as

AnimalsCrosses, GeneticDiabetes ComplicationsDiabetes Mellitus, Type 2Disease Models, AnimalInfarction, Middle Cerebral ArteryMaleMiceMice, Inbred C57BLMice, TransgenicMutationNitric OxideNitric Oxide Synthase Type IIIPhosphorylationStrokeTreatment OutcomeNitric OxideNitric Oxide Synthase Type IIINos3 protein, mousediabetes mellitusendothelial cellsnitric oxide

Identifiers

PMID23988642
PMCPMC3864831
OpenAlexW1964072401

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.